Propanc Biopharma will combine every 10 shares into 1 to meet Nasdaq rules.

Oct 23, 2026, 6:20 PM ETNew sharesRead the original at globenewswire.com

Neutral

Propanc's split may help restore Nasdaq's $1 minimum share-price compliance, but it does not change its research. Its Phase 1b study is still only planned for 2027, so the story does not change the business outlook.

PPCB · Propanc Biopharma, Inc.

AI read · Neutral

The AI's read

The change may help Propanc meet Nasdaq's minimum share-price rule and keep its listing. But it does not move PRP closer to testing in people. The Phase 1b study is still planned for the first quarter of 2027, so the story does not change the company's business outlook.

Get alerts for PPCB

Follow Propanc Biopharma, Inc. (PPCB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PPCB

Free on the App Store and Google Play, or on the web.